COMPANY

TScan Therapeutics

HQ: Waltham, MA source · tscan.com ↗ · New England

Keywords: oncology cancer cell therapy solid tumors solid tumor hematology AML Head and Neck Cancer Cervical Cancer Autoimmune Diseases Ulcerative Colitis Multiple Sclerosis Scleroderma Ankylosing Spondylitis Celiac Disease Non-radiographic Axial Spondyloarthritis Birdshot Chorioretinitis Non-small Cell Carcinoma Melanoma Ovarian Cancer Anogenital Cancers HPV - Anogenital Human Papilloma Virus Infection HPV-Related Cervical Carcinoma HPV-Related Carcinoma HPV-Related Squamous Cell Carcinoma HPV-Related Malignancy HPV-Related Adenocarcinoma HPV Positive Oropharyngeal Squamous Cell Carcinoma HPV-Related Adenosquamous Carcinoma HPV-Associated Vaginal Adenocarcinoma HPV-Related Endocervical Adenocarcinoma HPV-Related Anal Squamous Cell Carcinoma HPV-Related Verrucous Carcinoma HPV-Related Penile Squamous Cell Carcinoma HPV-Related Vulvar Squamous Cell Carcinoma HPV Positive Rectal Squamous Cell Carcinoma Non Small Cell Lung Cancer HPV16 Related Cancers Sarcoma Uveal Melanoma NUT Carcinoma ALL Renal Clear Cell Carcinoma

Location: Waltham, MA · source · Sep 30, 2026

Profile checked Oct 10, 2026

$30.0MRaised (2 yrs)9Trials (company is sponsor)

Timeline

Jun 18, 2026 Trial start Phase 3: A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation source ↗
Sep 9, 2025 Trial start —: A Long Term Follow-up Study of TScan TCR-T Products source ↗
Dec 26, 2024 Raise Follow-on offering — Registered direct: $30M (total, as published), announced Dec 26, 2024. Source: company release on GlobeNewswire. source ↗
Dec 23, 2024 Debt Debt financing: $52.5M (up to, as announced), announced Dec 23, 2024. Source: SEC filing. source ↗
May 6, 2024 Trial start Phase 1: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors source ↗
Jun 26, 2023 Trial start —: A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors source ↗
Jan 3, 2023 Trial start —: A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease source ↗
Nov 1, 2022 Trial start Phase 1: A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA) source ↗
Feb 26, 2021 Trial start —: A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells. source ↗
Dec 17, 2020 Trial start —: Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors source ↗
Apr 9, 2020 Trial start —: Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes source ↗

Upcoming milestones

Dec 30, 2026 (ESTIMATED) · Phase 1 · A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors · NCT05973487
2029-06 (ESTIMATED) · Phase 3 · A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation · NCT07702578
2040-09 (ESTIMATED) · · A Long Term Follow-up Study of TScan TCR-T Products · NCT06976736

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $30.0M · Debt: $52.5M. Last 2 years.

Dec 26, 2024 Follow-on offering — Registered direct: $30M (total, as published), announced Dec 26, 2024. Source: company release on GlobeNewswire. source ↗
Dec 23, 2024 Debt financing: $52.5M (up to, as announced), announced Dec 23, 2024. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT05473910	A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)	Phase 1	Active, not recruiting	Nov 1, 2022	Jun 1, 2026 (actual)
NCT07702578	A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation	Phase 3	Active, not recruiting	Jun 18, 2026	2029-06 (estimated)
NCT06587828	A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease	Not listed	Completed	Jan 3, 2023	Sep 10, 2026 (actual)
NCT05230186	A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.	Not listed	Completed	Feb 26, 2021	Dec 20, 2024 (actual)
NCT05973487	A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors	Phase 1	Active, not recruiting	May 6, 2024	Dec 30, 2026 (estimated)
NCT05812027	A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors	Not listed	Active, not recruiting	Jun 26, 2023	Jan 1, 2026 (estimated)
NCT06976736	A Long Term Follow-up Study of TScan TCR-T Products	Not listed	Recruiting	Sep 9, 2025	2040-09 (estimated)
NCT04680416	Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors	Not listed	Withdrawn	Dec 17, 2020	Aug 4, 2021 (actual)
NCT04397900	Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes	Not listed	Completed	Apr 9, 2020	Apr 12, 2021 (actual)